Pediatric Peptic Ulcer Disease: Scope-and-Treat, Not Test-and-Treat

This narrative review consolidates 2023 ESPGHAN/NASPGHAN guidance on pediatric peptic ulcer disease, including age-specific acid suppressant dosing and susceptibility-based Helicobacter pylori eradication that pediatric pharmacists must operationalize.

peptic ulcer diseaseHelicobacter pyloriproton pump inhibitorsomeprazolelansoprazoleesomeprazolepantoprazolefamotidineclarithromycinamoxicillinmetronidazolebismuthpediatric gastroenterologynarrative reviewNSAID ulcersantibiotic resistanceESPGHANNASPGHAN Pediatric Pharmacy

Background Information

Pediatric peptic ulcer disease demands tailored management strategies beyond adult protocols.

Peptic ulcer disease (PUD) in children requires different diagnostic and therapeutic approaches than adults due to unique pediatric challenges. The review highlights guideline-directed strategies, emerging antibiotic resistance, and age-appropriate management for pediatric PUD. Emphasizes the need for tailored pediatric approaches, assessing Helicobacter pylori resistance, and implementing specific follow-up protocols. Guideline-directed, age-specific care improves outcomes in pediatric peptic ulcer disease.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Martinez CA, Castillo P, Medina AL, Felipez LM

Citation: Martinez CA, Castillo P, Medina AL, et al. Peptic Ulcer Disease in Pediatrics: A Comprehensive Review. Pediatrics in review. 2026;47(9):512-523. doi:10.1542/pir.2025-006894

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →